INSERM

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease

Retrieved on: 
Monday, November 6, 2023
Euronext, The Michael J. Fox Foundation, Medical research, Swiss Federal Institute of Aquatic Science and Technology, MJFF, Teaching hospital, Clinical research, SCI, Research, INSERM, CHUV, Rehabilitation, Parkinson's disease, EPFL, Spinal cord, Swiss, ARC, Movement, Patient, Pharmaceutical industry, Medical device, Electric light, Nature Medicine

The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.

Key Points: 
  • The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.
  • The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France’s National Institute of Health and Medical Research (INSERM).
  • Fox Foundation for Parkinson’s Research (MJFF) to implant the ARC-IM System and investigate the effect of ARC Therapy in six additional participants with Parkinson’s disease.
  • This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson’s disease.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

Retrieved on: 
Wednesday, October 4, 2023
University of Geneva, Patent, Insulin resistance, Tonix Pharmaceuticals, Migraine, University, Magnesium, Prader–Willi syndrome, European Patent Office, INSERM, Feeding disorder, Oxytocin, IP, EPO, Patient, European Patent Convention, Pharmaceutical industry

CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

Key Points: 
  • CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No.
  • The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations.
  • This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.
  • “We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences

Retrieved on: 
Thursday, June 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, NETS, Bispecific monoclonal antibody, Collaboration, Drug development, Cell death, CD127, TNF, Neutrophil, IL-7, Chromatin, Survival, INSERM, End organ damage, Interleukin, Antibody, Neoplasm, Research, Inflammation, Cytoplasm, Fibrosis, Patient, Translational research, Clinical & Translational Immunology, Neutrophil extracellular traps, ISIN, Mouse, Mnemos EP, Poster, Cytokine, PD-1, TRIM21, Conference, Interferon, Pharmaceutical industry, Vaccine, Transplant

Dr Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, commented: “We are very proud to share our latest scientific advances on our innovative pre-IND research programs with the international scientific community.

Key Points: 
  • Dr Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, commented: “We are very proud to share our latest scientific advances on our innovative pre-IND research programs with the international scientific community.
  • We are looking forward to progressing these programs with strategic partners into clinical stage”.
  • Dr Aurore Morello, Head of Research of OSE Immunotherapeutics, said: “The latest data featured in our communications highlight the value and therapeutic potential of our pre-IND assets.
  • BiCKI®-IL-7, our bispecific anti-PD1/IL-7 program, presents an innovative cytokine approach, selectively targeting tumor-specific T-cells to improve the quality and durability of memory T-lymphocyte responses.

Brenus Pharma announces its international Scientific Committee

Retrieved on: 
Wednesday, June 7, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, CSO, Education, Personalized medicine, Organizational founder, INSERM, Research, Doctor of Philosophy, Precision, STC, Patient, Sidney Kimmel Comprehensive Cancer Center, Colorectal cancer, Immune system, NL, Dijon, Immunology, Society, Vaccine, Nursing

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.

Key Points: 
  • Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
  • This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
  • The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
    Pr François GHIRINGHELLI MD, PhD.
  • Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.

Expert.ai Launches AI Platform for Life Sciences

Retrieved on: 
Tuesday, May 16, 2023
EBSCO, Drug discovery, Electronic health record, INSERM, Privacy, Interventions, Literature, Clinical trial, Publication, Platform, Machine learning, The New England Journal of Medicine, Sanofi, Medical Subject Headings, Proposition, Health, ROI, Conference, Social media, Geography, Medical device, Pharmaceutical industry

New expert.ai Platform for Life Sciences has been chosen as a "Best of Show" finalist for 2023 Bio-IT Awards;

Key Points: 
  • New expert.ai Platform for Life Sciences has been chosen as a "Best of Show" finalist for 2023 Bio-IT Awards;
    The Platform combines industry language models and AI-based natural language capabilities transforming health and scientific data into insights.
  • BOSTON, May 16, 2023 /PRNewswire/ -- Expert.ai , the industry leader in providing AI-powered language solutions to enterprises, today announced availability of the expert.ai Platform for Life Sciences.
  • Through a hybrid AI approach combining natural language tools, enterprise language models and machine learning, the expert.ai Platform for Life Sciences fundamentally shifts the way unstructured medical and scientific data is monitored, understood, analyzed and collated.
  • The expert.ai Platform for Life Sciences offers an effective way to improve efficiency.

Dyslexia Virtual Event Offers Educators Up-To-Date Professional Knowledge to Improve Reading Outcomes for Millions of Learners

Retrieved on: 
Tuesday, May 2, 2023
The Hard Word, Learning, Journalism, Parent, Yale Center for Emotional Intelligence, INSERM, Hard, American Public Media, Learning Ally, Research, Brain, Experiment, Movement, Creativity, Literacy, Science, Dehaene, School, Student, Child, Reading, Frustration, Cognition, Knowledge, Tutoring, Publishing, Dyslexia

Learning Ally, a national nonprofit working with U.S. schools to improve reading outcomes and equitable access to grade-level books, will host the two-day virtual event on June 7 and 8, 2023.

Key Points: 
  • Learning Ally, a national nonprofit working with U.S. schools to improve reading outcomes and equitable access to grade-level books, will host the two-day virtual event on June 7 and 8, 2023.
  • These experts focus on evidence-based reading instruction proven effective for all students, and especially critical for students with learning disabilities.
  • This year's Spotlight on Dyslexia theme, "Believe, Build and Bolster," will empower educators to believe in themselves, build new knowledge and teaching capacity, and bolster classroom instruction.
  • The event promises to deliver proven strategies, interventions, and accommodations to transform reading outcomes, and to continue the important dialogue about dyslexia in Learning Ally's community forums.

OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology

Retrieved on: 
Thursday, April 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Glioma, Pancreatic cancer, Myelocyte, Collaboration, AACR, Macrophage, Hepatocellular carcinoma, Myeloid tissue, INSERM, Patient, Translational research, Clinical & Translational Immunology, ISIN, Mnemos EP, TRIM21, B cell, Vaccine, Transplant

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from its Myeloid platform, at the 2023 American Association for Cancer Research (AACR) Annual Meeting held in Orlando (Florida) on April 14-19.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from its Myeloid platform, at the 2023 American Association for Cancer Research (AACR) Annual Meeting held in Orlando (Florida) on April 14-19.
  • Dr Aurore Morello, Head of Research of OSE Immunotherapeutics, comments: “Altogether, the data presented at the AACR meeting demonstrate that CLEC-1 acts as a new immune checkpoint in myeloid cells and highlight the CLEC-1/new ligand TRIM21 axis as a new target for cancer immunotherapy.
  • These latest data generated from our teams’ collaboration provide evidence to further support the preclinical evaluation of monoclonal antagonist antibodies targeting CLEC-1.
  • The findings presented also revealed a previously unrecognized function for CLEC-1 in myeloid cells as a specific sensor of non-homeostatic cell death.